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Running head: microangiopathy in HCV-positive diabetics   
ABSTRACT 
Background: patients with chronic hepatitis C have an increased risk of diabetes mellitus but the 
type and risk of developing diabetes-related complications have not yet been evaluated.   
Methods: in order to compare  the incidence of diabetic microangiopathy in patients with new onset 
diabetes without microangiopathy we recruited 54  hepatitis C virus positive and 119 negative 
patients from January 2005 to December 2006.  All patients were followed-up every 6 months for 
liver and diabetic complications and incidence of  cardiovascular diseases up to December 2012 
when data were retrospectively analyzed.   
Results: the 2 cohorts were comparable at enrolment except for mean body mass index, obesity rate 
and family history of diabetes (p=0.007). After 7.2 years of follow-up,  13 (24.1%) positive and 37 
(31%) negative patients showed at least one microangiopathic complication (p= 0.34), 5 (9.3%) 
positive and 13 (10.8%) negative patients reported cardiovascular diseases (p=0.2). Fourteen 
(24.5%) positive compared to none negative patient developed liver-related complications 
(p=0.0003). One positive patient died due to HCC, 1 negative patient died for myocardial infarction 
(p= 0.3). Increasing age (HR= 1.04, 95%CI: 1.00-1.07, p= 0.04) and being smoker (HR= 2.94, 
95%CI: 1.06-8.17, p= 0.04) were positively associated to diabetic complications.   
Conclusions: incidence of microangiopathy is not significantly different in diabetics with or 
without chronic hepatitis C.     
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INTRODUCTION 
Type 2 diabetes mellitus (T2DM) which develops as a complication of advanced liver disease is a 
well-known condition defined “hepatogenous diabetes” (1).  However, even if T2DM is considered 
clinically different from the “classical” DM, due to the fact that it is less frequently associated with 
microangiopathy (2-5), it is not recognized by the American Diabetes Association and the World 
Health Organization as a specific independent entity (2).  This statement mainly derives from 
results of cross-sectional studies including patients with dissimilar etiologies  of  liver cirrhosis. 
Hepatitis C Virus (HCV) seems to increase the risk of incident T2DM in predisposed individuals 
(6,7) as well as the risk of cardiovascular diseases (8), independently of  stage of liver disease as 
reported by Knobler et al. who observed a prevalence of T2DM of 33% in non-cirrhotic patients 
with chronic hepatitis C (CHC) compared with 5.6% in a control group (9).   The hypothesized 
mechanisms by which HCV can induce the development of T2DM are not clearly understood but 
these include the stimulus to the production of Tumor Necrosis Factor-α (TNF-α), the serine 
phosphorylation of the insulin receptors (IRS) and the overexpression of suppressor of cytokines 
(SOC-3) (10).  Many studies (11-15) reported the clinical consequences of T2DM on CHC outcome 
but very few studies addressed the issue of microangiopathic complications among patients with 
CHC only, developing T2DM  (16).  The primary aim of our study was to assess the incidence of 
diabetic microangiopathy in a cohort of CHC patients with new-onset T2DM and without baseline 
microangiopathic complications throughout a 7-year follow up.  In order to establish whether such 
incidence was different from that observed among diabetic patients without CHC, we compared the 
occurrence of diabetic complications in the CHC cohort with that of a similar control group of new-
onset T2DM, HCV-negative patients without baseline microangiopathy, comparable for age, T2DM 
duration and length of follow up.  Secondary aim was to compare the cumulative incidence rate of 
macroangiopathic complications (coronary artery disease (CAD), peripheral artery diseases) 
between the two  cohorts. 
 
PATIENTS AND METHODS 
The medical records of 612 consecutive patients with CHC examined between January 2005 and 
December 2006 in two academic centers of North-Western Italy (the Gastrohepatologic Clinic of 
Molinette Hospital, Turin, Italy and the Gastroenterology Division of San Luigi Hospital, 
Orbassano, Italy) were retrospectively reviewed. Patients were included into the present study if 
they fulfilled the following criteria at baseline: age > 18 years; positive results for HCV-RNA by 
polymerase chain reaction (PCR); CHC at liver biopsy; new-onset T2DM; documented baseline 
informations regarding: gender, body mass index (BMI), viral load, genotype, liver histologic 
staging, glucose plasma level, glycosylated hemoglobin (HbA1c),  smoking status, arterial 
hypertension (AH), family history for T2DM. Exclusion criteria were: known carriers of T2DM 
with or without chronic complications (CAD, stroke, retinopathy, nephropathy, neuropathy, 
peripheral artery disease), decompensated cirrhosis, active alcohol intake, presence of other 
concomitant diseases or conditions such as haemochromatosis, Wilson's disease, drug-related liver 
disease, autoimmune hepatitis, HBsAg  carriership, HIV infection, primary biliary cirrhosis, α1-
antitrypsin deficiency, neoplasia. Overall, 494 non-diabetic patients were excluded and of 
remaining 118 diabetic patients, 64 (54.2%) were known carriers of T2DM or showed T2DM-
related chronic complications at diagnosis.  Thus, 54 patients were enrolled in the CHC cohort.  Of 
these 54 patients, 22 (40.7%) were treated during the follow up with Interferon (IFN)-based therapy 
and ribavirin (RBV) for 24 or 48 weeks according  to HCV genotype. A sustained virologic 
response (SVR) was defined as the HCV-RNA clearance 6 months after the end of treatment. 
Patients who did not achieve this result were considered relapsers or non responders (NRs).   
As control group,  we considered 1212 patients with T2DM  consecutively recruited at the Diabetic 
Clinic of the University of Turin, Italy, from January 2005 to December 2006.  A detailed 
computerised database regarding demographic, clinical and pharmacological features of the entire 
cohort was available.  Of 1212 patients, we selected for the study only HBsAg-negative, anti-HCV-
negative patients  with documented new-onset T2DM, without any chronic complication and 
without alcoholic liver disease.   One thousand patients (82.5%) were known carriers of T2DM and 
were excluded; of the remaining 212 patients with a newly diagnosed T2DM, 93 (43.8%) showed 
chronic diabetic complications at baseline.  Thus, 119 patients were enrolled in the HCV-negative 
cohort as controls.   Patients' flow is reported on Figure 1. 
Each patient of both cohorts was examined at least every 6 months during follow up: they had their 
blood pressure and glycated haemoglobin measured at each visit. Liver function tests and 
abdominal ultrasound were also performed in HCV-positive  patients.  Moreover, all patients were 
screened yearly for chronic complications related to DM and were followed up for a mean time of  
7.2 (standard deviation: 1.3)  years; their clinical outcomes were recorded.  At the end of a similar 
length of follow up, we performed a comparative analysis of the incidence of T2DM complications 
and  liver cirrhosis adjusted for several potential confounders. 
 
 
 
Definitions 
Smokers were defined as persons smoking more than one cigarette per day or known to have 
smoked within three years before the study recruitment. 
BMI was calculated as weight in kilograms divided by the square of the height in meters.  Arterial 
blood pressure values reported were the means of the last three determinations.  Hypertension was 
defined as a systolic and/or diastolic blood pressure of 140/90 mmHg or higher and/or a current 
anti-hypertensive treatment (17).   
According to the criteria recommended by the Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, T2DM was defined as fasting plasma glucose ≥ 126 mg/dl (7 
mmol/l) in two separate measurements (18). 
Liver complications 
Patients were considered to have liver failure if they met any of the following criteria: ascites 
confirmed by abdominal ultrasound or computed tomography (CT), bleeding oesophageal varices, 
jaundice with bilirubin > 35 µmol/L or hepatic encephalopathy.  Patients were considered to have 
hepatocellular carcinoma (HCC) if the diagnosis was cyto-histologically confirmed, or if two 
coincident imaging techniques (ultrasound, CT or magnetic resonance imaging) showed a focal 
lesion > 2 cm with arterial hypervascularization or if one imaging technique showed a focal lesion > 
2 cm with arterial hypervascularization in the presence of  alpha-fetoprotein > 400 ng/ml. 
Liver transplantation and mortality (classified as liver or non liver-related) were recorded. 
 
Diabetes complications 
The diagnosis of cardiovascular disease was based on documented events that were recorded by the 
diabetologists (i.e. angina, myocardial infarction, coronary artery by-pass graft or another invasive 
procedure to treat CAD, transient ischemic attack, stroke, gangrene, amputation, vascular surgery, 
intermittent claudication, absent foot pulses and abnormal brachial and posterior tibial blood 
pressure documented using Doppler techniques). 
Retinopathy was diagnosed via an ophtalmoscopic examination and/or retinal photography.  A 
fundoscopy was performed through dilated pupils by an ophthalmologist experienced with diabetic 
retinopathy.  In case of retinopathy (any degree), a retinal photograph was taken, in accordance with 
the European protocol for diabetic retinopathy.  Nephropathy was established by  an albumin 
excretion rate (AER) higher than 20 µg/min in at least 2 out of 3 urine collections within 6 months 
(immunoturbidimetric method), gross proteinuria or elevated serum creatinine levels.  Distal 
symmetric polyneuropathy was diagnosed by the presence of neuropathic symptoms, an abnormal 
vibration perception threshold, the absence of ≥ 2 ankle or knee reflexes and/or an abnormal 
electromyographic test.  Autonomic neuropathy was diagnosed by a loss of heart rate variability or 
postural hypotension. 
 
Histology 
The degree of liver fibrosis was assessed by one pathologist according to the Ishak scoring system  
(19).  During the follow-up, subjects were classified as cirrhotic by a second liver biopsy or, in the 
absence of bioptic examination, if they showed unequivocal evidence of portal hypertension 
(presence of esophageal varices not associated with portal vein thrombosis),  or a particular 
ultrasound pattern (nodular contour, diminished hepatopetal flow, collaterals) or a typical serology 
(platelets < 80000 x 109 /L, albumin < 3.5 g/l, clotting factors < 50%) or by liver elastography 
adopting the stringent recommendations suggested by Kettaneh et al. and showing a liver stiffness > 
14.5 KiloPascal (20). 
 
 
Statistical analysis 
Baseline continuous variables were summarized with means (and standard deviations, SD); 
categorical variables were reported as frequencies (and percentages).  The two cohorts were 
compared at baseline to identify meaningful differences for clinical or demographical 
characteristics by using either a t-test (for continuous variables) or a Chi-square (or Fisher) test (for 
categorical variables).  The cumulative incidence of specific complications of T2DM was firstly 
compared as simple proportions by Chi-square (or Fisher) tests, considering all the events at the end 
of the follow up.  To compare the risk of micro and macroangiopathic complications between the 
two cohorts, accounting for some known risk factors, the Cox proportional-hazard model was used.  
The estimated Hazard Ratios (HR), with their 95% Confidence Intervals (95% CI) were reported 
both as crude estimate and adjusted for age, gender, smoking habits and diabetes therapy. 
RESULTS 
The results of  the comparison of the two cohorts are summarised in Table 1. 
At baseline, the two cohorts were comparable for age, gender, disease duration and stage but they 
differed for BMI, obesity rate, liver disease, family history of T2DM, type of therapy and use of 
statins. Patients with CHC showed lower BMI (p<0.0001) and obesity rate (p=0.008); expectedly, 
pre-existing cirrhosis (61.4% vs 2.5%, p<0.0001)  and alterations of ALT/GGT levels were more 
frequently found among HCV-positive patients  (p<0.0001).  A higher percentage of HCV-negative 
patients reported family history for T2DM compared with HCV-positive patients (86.3% vs 56.6%, 
p= 0.003). At baseline, a higher proportion of patients with CHC were treated with insulin (12.9% 
vs 1.6%, p= 0.008) but a significantly lower percentage of them were given statins (9.3% vs 58%, 
p<0.0001). 
Among patients without cirrhosis at baseline, 2/116 (1.72%) in the HCV-negative cohort developed 
cirrhosis during the follow-up, while 2/20 (10%) in the HCV-positive cohort showed a cirrhotic 
evolution (p<0.0001).  
After a mean follow-up of  7.2 years, 171 out of 173 patients were re-assessed; none was lost to 
follow up: one (0.84%) HCV-negative patient died for myocardial infarction and one (1.85%) 
HCV-positive patient died for HCC (p= 0.3). BMI did not significantly change among HCV-
positive  (mean difference from baseline: -0.58, SD: 1.88) and HCV-negative patients (-0.44, SD: 
2.39), p=0.69, as well as mean HbA1c levels (- 0.42±1.48 vs – 0.82±1.84, p= 0.21) suggesting  a 
comparable good glycemic control. 
T2DM-related and liver-related complications observed during follow up are reported in Table 2. 
Microangiopathy was found in 24.1% (95%CI= 14.6-36.9) of patients with CHC and in 31% 
(95%CI=23.5-39.9) of HCV-negative patients (p= 0.34); 3 (5.5%) HCV-positive patients 
experienced myocardial infarction compared to 2 (1.68%) HCV-negative patients (p= 0.16) while 
stroke was observed in 3.7% and 9.2% respectively (p= 0.20).         
As expected, liver-related events were more frequently found among HCV-positive patients than 
among HCV-negative patients who did not show any hepatic complications; in the CHC cohort, 5 
(9.25%, p= 0.001)  patients had ascites, 6 (11.1%, p=0.0003) developed HCC and 2 (3.7%, p= 0.04) 
underwent orthotopic liver transplant.   
Among HCV-negative cohort,  49 (58.3%) developed “de novo” AH compared to 3 (10%) HCV-
positive diabetics (p=<0.0001). 
At the end of follow up, therapy of T2DM was different between the two cohorts: significantly 
more HCV-negative diabetics were treated with insulin sensitizers (77.3% vs 54.3%, P= 0.007) 
compared with patients with CHC; conversely, a significantly higher proportion of HCV-positive 
patients was given insulin (21% vs 6.7%, p<0.0001) or  diet only (24.5% vs 15.9%, p=0.003). 
Out of 22 HCV-positive patients treated with Peg-IFN + RBV, 8 (36.3%) obtained a SVR: none 
developed micro/macroangiopathic complications.   
In order to adjust the comparison between the two cohorts, accounting for known risk factors for 
T2DM-related complications, we used a Cox proportional hazard risk model; results are reported in 
Table 3. 
Based on a multivariable Cox regression analysis, HCV positivity was not associated to an 
increased risk of developing T2DM-related complications (HR= 0.74, 95%CI=0.33-1.71, p= 0.49).  
The risk of complications was positively associated with increasing age (in years) (HR= 1.04, 
95%CI: 1.00-1.07, p= 0.04) and being smoker at enrolment (HR= 2.94, 95%CI: 1.06-8.17, p= 0.04) 
were positively associated to micro/macroangiopathic complications.     
 
 
  
 
 
 
DISCUSSION 
The present study did not find any meaningful difference in the incidence of both microangiopathic 
and macroangiopathic complications between patients with newly diagnosed T2DM with or without 
CHC, after a comparable duration of disease and length of follow up and despite the lower BMI and 
obesity rate observed among HCV-positive patients.   These data are apparently in contrast with 
those previously reported (2,4,5).  Marchesini et al. (4) showed a lower prevalence of micro- and 
peripheral macroangiopathy in diabetic cirrhotics compared with non-cirrhotic diabetic patients; to 
explain the difference with our study, it should be considered that the study design was cross-
sectional, the etiology of cirrhosis was heterogeneous (Hepatitis B Virus, HCV, alcohol, primary 
biliary cirrhosis, Wilson’s disease, alfa1-antitrypsin deficiency, hemochromatosis) and the duration 
of diabetes was significantly longer in diabetic patients without cirrhosis.  Holstein et al. (2) 
reported an overall rate of 8% regarding retinopathic complications in 52 patients with cirrhosis and 
T2DM; no T2DM-related complications were observed among 20 patients with newly diagnosed 
T2DM during the  follow-up.  However, the study design was not controlled, only 19% of patients 
were HCV-positive and the follow-up period was short (3.9 years).   Kuriyama et al. (5) showed a 
significantly lower incidence of microangiopathy among diabetics with chronic liver disease 
(mainly HCV-positive) compared with a matched group of diabetic patients without liver disease. 
Main criticisms are the cross-sectonal study design and the fact that the diabetic disease duration 
was not reported.   In contrast with the abovementioned studies, a recent study (16) reported a 
significantly higher prevalence of T2DM complications among HCV-positive diabetics compared 
with HCV-negative diabetics; however, no data regarding baseline liver histology, methods to 
assess microangiopathy/macroangiopathy and duration of  T2DM were described.  Duration of 
diabetic disease is crucial in determining the real incidence of  T2DM-related complications; to 
date, no study recruited patients with only newly diagnosed T2DM making unreliable the 
comparison between two cohorts with different duration of disease.  To the best of our knowledge, 
this is the first study which addressed this issue considering only patients with “de novo” diagnosis 
of T2DM and without baseline micro/macroangiopathy.  In spite of these strict selection criteria, we 
cannot exclude that some patients without HCV with newly diagnosed T2DM had pre-existing 
T2DM which remained undiagnosed due to a long lasting preclinical stage (4).   On the contrary, 
patients with CHC were followed up with periodic glycemic controls; thus, in this cohort of patients 
the diagnosis of T2DM was made in the preclinical stage.  In other words, it is likely that duration 
of diabetic disease is underestimated among ordinary diabetics compared with  regularly followed 
up HCV-positive diabetics.    
In our study, nearly 63% of HCV-positive patients with new onset T2DM were cirrhotic and 2 
(10%) more patients developed cirrhosis during the follow up compared with 2 (1.7%) in the HCV-
negative cohort (p<0.0001); it is possible, however,  that incidence of liver cirrhosis among HCV-
negative diabetics may be underestimated due to less stringent hepatologic follow up.  We think that 
a considerable proportion of these patients are expected to never develop diabetic complications, 
because of a reduced, cirrhosis-related life expectancy; in fact, in cirrhotic patients with T2DM, the 
most recurrent cause of death is liver failure (3,21,22) .  In a previous study (15) , we evaluated the 
impact of T2DM on the incidence of liver-related events and overall survival among patients 
suffering from CHC followed up for a mean period of 11 years after IFN-based plus RBV therapy.  
We showed that patients with baseline T2DM had a higher risk of HCC development and liver 
decompensation than non-diabetic patients; our results were recently confirmed by other studies 
(23,24). 
It has been previously suggested that, in patients with viral cirrhosis, T2DM is not associated with 
an increased risk of peripheral macroangiopathy (4), CAD (2,4) and cerebrovascular disease (2,25); 
the coagulation abnormalities and thrombocytopenia (26,27) as well as the low serum cholesterol 
levels (28) and low arterial blood pressure frequently seen in cirrhosis have been proposed as 
possible protective factors.  In our study, macroangiopathic complications were not different 
between the two groups but the relative small number of patients does not allow to draw definite 
conclusions. 
Finally, 8/22 (36.4%) HCV-positive patients treated with Peg-IFN + RBV cleared the virus and 
none developed micro/macroangiopathic complications; our data confirm the results of a recent 
study (29) showing that antiviral treatment is associated with improved renal and cardiovascular 
outcomes in diabetic patients with concomitant HCV infection.  Moreover, results and conclusions 
of our study did not change after exclusion of HCV-positive patients achieving SVR.  
Certain methodological limitations should be taken into consideration when interpreting the results 
of the current study.    Firstly, the retrospective nature of the study might be a potential source of 
selection bias. However, baseline discrepancies regarding  HCV-positive diabetics/HCV-negative 
diabetics are not due to an arbitrary selection but represent well known differences between distinct 
populations and were carefully considered in the multivariate analysis.  
Secondly, due to the small number of patients included, we can only exclude with a statistical 
power of 80% the existence of large differences (corresponding to HRs > 2.3) between the two 
groups regarding T2DM complications; for this reason, a larger prospective multicenter controlled 
study would be recommended.  
In conclusion, according to our data the risk of microangiopathic complications  in patients with 
CHC and new onset T2DM is similar to that observed among patients with newly diagnosed T2DM 
without CHC; however, the unfavourable natural history of HCV-positive cirrhotics due to liver 
complications  is likely to make less evident the clinical impact of  microangiopathy.  There is still 
need for large prospective controlled studies in order to evaluate the outcome of T2DM in CHC. 
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Figure legend: 
 
Figure 1. Flow of recruited patients 
 
DM: dibetes mellitus 
HCV: hepatitis C virus 
 
 
 
Table 1.  Comparison of Hepatitis C Virus positive vs Hepatitis C Virus negative   cohorts of 
newly diagnosed type 2 diabetic patients 
                                                       HCV positive                      HCV negative                            p-value 
 N. of patients                     54       119 
 
 Mean age (± SD)      55.7 (±10.4)  57.7 (±10.8)  0.24 
 Male gender 32 (59.3%) 56 (47%) 0.14 
 Mean BMI (± SD)  26.6 (±4.2)   29.7 (±5.3)   <0.0001 
 Obese patients 12 (22.2%) 49 (41.2%) 0.008 
 Arterial hypertension (%)  14/54 (25.92%) 35/119 (29.41%) 0.64 
 Smokers (%)  11/54 (20.37%) 26/119 (21.85%) 0.41 
 Family history of DM (%) 56.67% 86.3% 0.003 
 Mean glycemic (mg/dl)  
 values (± SD) 
165.4 (±47.1) 151 (±45.4) 0.06 
 Mean Hba1c (g/dl) 
 values (± SD) 
 7.4 (±1.5)   7.9 (±2.0)   0.14 
 Mild liver fibrosis (1) 9 (16.7%) - - 
 Severe liver fibrosis (2)  11 (20.3%) - - 
 Cirrhosis (%)  34/54 (62.9%)   3/119 (2.52%) <0.0001 
 Mean ALT (UI/l)  
 values (±SD) 
121.1(±91.7) 36.3 (±28.4) <0.0001 
 Mean GGT (UI/l)  
 values (±SD) 
 134.5 (±266.5) 45.7 (±48.4) 0.003 
Statins use 5 (9.3%) 69 (58%) < 0.0001 
DM therapy                                                       0.008 
 Diet only (%) 23/54 (42.60%) 57/119 (47.9%) 
 
 Oral hypoglycemic  
 agents (%) 
24/54 (44.44%)  60/119 (50.42%) 
 
 Insulin (%) 7/54 (12.96%)  2/119 (1.68%) 
 
 
HbA1c= glycated hemoglobin  ALT= Alanine Transaminase 
GGT= Gamma Glutamyl Transpeptidase 
(1) Ishak staging score = 0-3         (2) Ishak staging score = 4-5 
 
 
Table 2.   Incidence of diabetes mellitus related complications in Hepatitis C positive vs 
Hepatitis C negative cohorts of newly diagnosed type 2 diabetic patients 
 
                                                      HCV positive                           HCV negative                            p-value 
 N. of patients     54        119 
 
 Overall microangiopathic                 
events (%) 
13 (24.1%) 37 (31.09%)  0.34 
 Retinopathy (%) 5 (9.26%) 15 (12.6%)   0.47 
 Nephropathy (%)   5 (9.26%)  12 (10.08%)   0.87 
 Neuropathy (%)   3 (5.56%)  6 (5.04%)   0.8 
 Ischaemic foot ulcer (%) 0 (0%) 4 (3.36%)   0.17 
 Coronary artery  
 disease (%)    
3 (5.55%) 2 (1.68%)  0 .16 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.  Association between chronic hepatitis C, other known risk factors and 
development  of diabetes-related complications: multivariable Cox  regression  analysis 
 
                                                           hazard ratio                     confidence intervals                      p-value 
 Chronic hepatitis C 0.74   0.33-1.70  0.48 
 Male gender 1.23  0.57-2.66   0.58 
 Age 1.04    1.00-1.07 0.04 
 Body mass index   1.04     0.98-1.10  0.23 
 Current smokers (1)  2.94    1.06-8.17     0.04 
 Arterial hypertension   0.80   0.38-1.70   0.57 
 Oral hypoglycemic  
  agents (2) 
1.17  0.59-2.33   0.65 
Insulin therapy (2)   0.90          0.11-7.38 0.92 
 
(1) Reference category: never smokers 
(2) Reference category: diet only 
 
 
 
 
 
